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Abstract
The NIH sponsored a scientiﬁc workshop, “Soy Protein/Isoﬂavone Research: Challenges in Designing and Evaluating
Intervention Studies,” July 28–29, 2009. The workshop goal was to provide guidance for the next generation of soy
protein/isoﬂavone human research. Session topics included population exposure to soy; the variability of the human
response to soy; product composition; methods, tools, and resources available to estimate exposure and protocol
adherence; and analytical methods to assess soy in foods and supplements and analytes in biologic ﬂuids and other
tissues. The intent of the workshop was to address the quality of soy studies, not the efﬁcacy or safety of soy. Prior NIH
workshops and an evidence-based review questioned the quality of data from human soy studies. If clinical studies are
pursued, investigators need to ensure that the experimental designs are optimal and the studies properly executed. The
workshop participants identiﬁed methodological issues that may confound study results and interpretation. Scientiﬁcally
sound and useful options for dealing with these issues were discussed. The resulting guidance is presented in this
document with a brief rationale. The guidance is speciﬁc to soy clinical research and does not address nonsoy-related
factors that should also be considered in designing and reporting clinical studies. This guidance may be used by
investigators, journal editors, study sponsors, and protocol reviewers for a variety of purposes, including designing and
implementing trials, reporting results, and interpreting published epidemiological and clinical studies. J. Nutr. 140:
1192S–1204S, 2010.
Introduction
The NIH sponsored a scientiﬁc workshop, “Soy Protein/
Isoﬂavone Research: Challenges in Designing and Evaluating
Intervention Studies,” July 28–29, 2009. The workshop goal
was to provide guidance for the next generation of soy protein/
isoﬂavone human research. Session topics included population
2 Supported by the NIH (Ofﬁce of Dietary Supplements, National Center for
Complementary and Alternative Medicine, National Cancer Institute, National
Institute of Arthritis and Musculoskeletal and Skin Disorders, National Institute
on Aging, Division of Nutrition Research Coordination).
3 Author disclosures: M. A. Klein, R. L. Nahin, J. I. Rader, L. U. Thompson, J. T.
Dwyer, Y. S. Kim, C. H. Pontzer, P. E. Starke-Reed, no conﬂicts of interest. M. J.
Messina regularly consults for companies that manufacture and/or sell soyfoods
and/or isoﬂavone supplements. T. M. Badger was a Scientiﬁc Advisor for the Soy
NutritionInstitute.C. M.WeaverservesontheScientiﬁcBoard ofPharmavite,LLC.
4 Any opinions, ﬁndings, conclusions, or recommendations expressed in this
publication are those of the authors and do not necessarily reﬂect the views of
the NIH or the U.S. FDA.
14 Current address: Ofﬁce of Dietary Supplements, NIH, 6100 Executive
Boulevard, Room 3B01, Bethesda, MD 20892.
1 Published in a supplement to The Journal of Nutrition. Presented at the
workshop “Soy Protein/Isoﬂavone Research: Challenges in Designing and
Evaluating Intervention Studies,” held in Bethesda, Maryland, on July 28–29,
2009, and sponsored by the NIH. The supplement coordinator for this supplement
is Marguerite A. Klein, Ofﬁce of Dietary Supplements, NIH. Publication costs for
this supplement were defrayed in part by the payment of page charges. This
publication must therefore be hereby marked "advertisement" in accordance with
18 USC section 1734 solely to indicate this fact. Supplement Coordinator
disclosure: Marguerite A. Klein, no conﬂict of interest. Supplement Guest Editor
disclosure: Terryl J. Hartman declares no conﬂict of interest. The opinions
expressedinthispublicationarethoseoftheauthorsandarenotattributabletothe
sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition.
* To whom correspondence should be addressed. E-mail: kleinm@mail.nih.gov.
1192S ã 2010 American Society for Nutrition.
First published online April 14, 2010; doi:10.3945/jn.110.121830.exposure to soy;
15 the variability of the human response to soy;
product composition; methods, tools, and resources available to
estimate exposure and protocol adherence; and analytical
methods to assess soy in foods and supplements and analytes
in biologic ﬂuids and other tissues. The intent of the workshop
was to address the quality of soy studies, not the efﬁcacy or
safety of soy.
To develop the guidance, the participants identiﬁed method-
ological issues relative to exposures and interventions that may
confound study results and interpretation. Scientiﬁcally sound
and useful options and solutions for dealing with these issues
were discussed. This guidance may be used by investigators,
journal editors, study sponsors, and protocol reviewers for a
variety of purposes, including the design and implementation of
trials, reporting results, and interpretation of published epide-
miological and clinical studies.
Background
Two important documents resulting from prior workshops and
an evidence-based review served as the background to the
current workshop. In 2005 the National Institute of Environ-
mental Health Sciences of NIH held 2 workshops, 1 to review
the literature to assess whether phytoestrogens could signiﬁ-
cantly affect hormonal and other endpoints in animals and the
other to develop strategies to address problems caused by batch-
to-batch variation in estrogenic compounds in animal diets. The
workshop results were reported in early 2008 (1). The key
ﬁnding of these workshops and report was that research results
are often confounded by unanticipated levels of phytoestrogens
in laboratory unpuriﬁed diets. Even though the protein content
of soy-containing animal diets was constant, there was signif-
icant batch-to-batch variability in estrogenic content of com-
mercial animal diets and this variability resulted in differences in
experimental outcomes. Much of the variability may be elim-
inated by using phytoestrogen-free diets, such as the AIN 93
semipuriﬁed diet, supplemented with a known quantity of
phytoestrogens (2,3). Although the National Institute of Envi-
ronmental Health Sciences workshops focused on animal
studies, they concluded that it is clear that variation in diet
components may also affect clinical studies. Hence, the NIH
questioned the quality of data from human studies.
NIH has supported research on soy in its many forms for a
range of outcomes. Results of clinical studies have been
inconsistent. Questions concerning which forms of soy might
be better for studies of speciﬁc health outcomes and at what
doses led the National Center for Complementary and Alterna-
tive Medicine and the Ofﬁce of Dietary Supplements, both of
NIH, to commission an evidence-based review of the literature,
“Effects of Soy on Health Outcomes,” through the Agency for
Health Care Research and Quality (AHRQ) (4). The review
summarized the formulations of soy products and/or soy food
used in clinical trials and the current evidence of the health
effects of soy and its constituents on the following health
outcomes: cardiovascular disease, menopausal symptoms, en-
docrine function, cancer, bone health, reproductive health,
kidney function, cognitive function, and glucose metabolism.
In addition, safety issues and drug interactions associated with
using soy were summarized.
The AHRQ evidence-based review, released in 2005 (4),
reported that about three-quarters of the 281 included trials
studied soy supplements with the remainder being trials of soy
foods. Fifty-seven percent of the soy supplement trials used
isolated soy protein with isoﬂavones, 36% used isoﬂavones
alone, and 6% used soy protein without isoﬂavones. Textured
soy protein was evaluated in 25% of soy foods trials and soy
ﬂour was evaluated in another 25%. The remaining 50%
evaluated soybeans alone, tofu alone, and other soy foods.
Isoﬂavone and soy protein doses varied widely, from 10 to 185
16
mg/d and 14 to 154 g/d, respectively. Only a few studies directly
compared doses. In addition, there was a considerable degree of
heterogeneity among the studies, including study design, inter-
vention duration, background diet, and controls. A large
number of studies suffered from inadequacies of reporting or
study design, thereby limiting conclusions.
If clinical studies are to be pursued, then study sponsors,
investigators, reviewers, and journal editors need to ensure that
the experimental designs are optimal and the studies properly
executed. How do we move forward?
Clinical research guidance
The current NIH workshop resulted in guidance, not require-
ments. This guidance is presented in the subsequent sections
with a brief rationale. The guidance is speciﬁc to soy research
and does not address nonsoy-related factors that investigators
should consider when developing protocols and operations
manuals, implementing studies, and reporting results.
Justiﬁcation for clinical research
Guidance.
Use caution when interpreting past studies; consider study age,
source, and quality; historical changes in test agents;
background inﬂuences; participant characteristics and het-
erogeneity; and intervention adherence and frequency of its
assessment.
Acquire information from previous studies on product char-
acterization, stability, and analytical methods used to deter-
mine product integrity.
Determine the quality, sample size, participant characteristics,
and heterogeneity of studies that may provide the foundation
for new studies.
Key points.
The relevance of cell culture and animal studies to human
clinical studies requires careful evaluation before translation
to clinical trials.
Epidemiological studies of Asian populations provide the
background for many clinical studies; the type of soy Asians
have traditionally consumed often differs from that con-
sumed by Americans and other Westernized populations and
from the majority of what has been studied clinically.
Few dose-response trials have been conducted in humans, so it
is difﬁcult to estimate with conﬁdence the threshold amount
of soy needed to exert various physiologic effects in vivo.
15 Unless otherwise noted, the term “soy” [Glycine max (L.) Merr.] is used
throughout this document to include whole soy in all its chemical complexity, as
well as isolated soy constituents (e.g. individual isoﬂavones or protein). When a
distinction needs to be made, speciﬁc terminology is used.
16 Isoﬂavone values are used as reported in the original literature and not converted
to aglycone equivalents unless they are labeled as aglycone equivalents. This
document uses the common spelling “aglycone.” The alternative is “aglycon,” the
preferred spelling of the International Union of Pure and Applied Chemistry.
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clinical research. Uncertainty exists even among experienced soy
researchers who attempt to interpret the hundreds of soy studies
published annually. These prior investigations may include
epidemiologic studies, human intervention trials, animal studies,
and cell culture studies. It is difﬁcult to synthesize results across
this wide range of study types and designs. The relative merits
and potential public health signiﬁcance of research reports using
different research models are continually debated.
In vitro studies. The source of the most confusion and
conﬂicting results is perhaps the use of supraphysiological levels
of isolated isoﬂavones or mixtures of isoﬂavones in cell cultures.
In vitro studies may over- or underestimate in vivo effects. The
relevance of these studies to in vivo human situations is
uncertain and their results should be interpreted with caution,
although they may be helpful in determining how soy may exert
effects at cellular and molecular levels (5).
Animal studies. Animal studies may also fail to predict
outcomes in humans due to a variety of reasons. Animal model
systems are not completely comparable to humans when
assessing disease progression, metabolism, or health effects of
testagentssuchassoy.Animalsmaybefedsoyatlevelsexceeding
what is typically found in Asian or Western diets or administered
tohumanresearchparticipants.Genistein,theprimaryisoﬂavone
in soybeans, may be administered to animals by injection, which
would bypass the gastrointestinal tract and liver and may also
exceedtheexposurepossiblebyreasonablehumanconsumption.
While dietary exposure in preclinical models is preferred, it is
critical that blood levels (total and aglycone) be evaluated and be
comparable to the blood levels observed in human populations
consuming isoﬂavone-containing products. Physiologically re-
levant dietary levels should be considered when appropriate.
Furthermore, isoﬂavone metabolism in rodents and nonhuman
primates differs markedly from that of humans (6). Finally, the
intestinalmicroﬂoraofrodentsandmonkeysismoreefﬁcientthan
microﬂora in humans at producing equol, the metabolite of the
isoﬂavone daidzein and, consequently, results of studies in these
species may not predict the effect of soy consumption in humans
(5).Itisimportanttonotethatalthoughthepreclinicalmodelshave
limitations,thesestudieshaveprovidedusefulinformationthathas
beensupportedbyresultsfromhumanclinicalandepidemiological
studies.Forexample,the7,12-dimethylbenz[a]anthraceneratand
athymic mousemammarytumor modelswerecriticallyimportant
in the development of tamoxifen and aromatase inhibitors as
frontline therapies for breast cancer. Additionally, the protective
effect from early life exposure to soy isoﬂavones in preclinical
models(7)wasveryusefulindemonstratingtheprotectionofearly
life exposure against breast cancer (8–11).
Epidemiological studies. Early epidemiological studies that
formed the foundation of our understanding of how to move
forward with clinical studies have been based on the foods
people in Asia have been eating. A major distinction between
epidemiological studies and clinical studies is that the popula-
tion-based studies are investigating soy intake as whole foods or
diets, whereas experimental research is usually based on
administration of isolated constituents. For more epidemiologic
information, see the “Soy exposure and intervention adherence”
section in this document.
Clinical studies. Interpreting previous clinical research is dif-
ﬁcult, but history may provide guidance. Over time, processing
and development of soy products have evolved, generally for the
purpose of improving food functionality (e.g. to promote water
retention or for use as a bleaching agent). As a result, different
soy constituents or constituents in different proportions may be
present in soy products consumed or studied today compared
with products fromearlier times.Therefore,whenevaluatingpast
studies, it is important that the published results contain detailed
informationonproductcharacterization.Itwouldalsobeusefulto
know the content of phytate, selenium, or other possible bioactives
(confounders) of intervention products. If the study product is still
available, it might be worthwhile to analyze its composition.
Furthermore, investigators must keep in mind that many clinical
studies involve administering soy in amounts that exceed what is
commonly consumed in Western or Asian populations.
Few dose-response trials have been conducted in humans, so it
is difﬁcult to estimate with conﬁdence the threshold amount of
soy neededtoexert physiologic effects in vivo.Mostclinicaltrials,
e.g., have used 40–90 mg/d of total isoﬂavones, with the AHRQ
evidence-based review reporting a range of 10–185 mg/d of total
isoﬂavones (4). In addition, the amount needed to exert beneﬁcial
effects may vary according to the condition under investigation. It
is possible that the amount of soy needed for health beneﬁts when
consumed over the course of a lifetime is lower than that needed
to produce beneﬁts in short-term clinical trials.
Product composition and integrity
Guidance.
Know and report the product source and supplier.
Analyze, describe, and report all the potential bioactive
constituents relevant to the study.
Conduct independent analyses of test and placebo agents
before, during, and after intervention, and report all
analytical methods used to determine product constituents.
Use appropriate and accurate terminology in describing test
agents.
Express isoﬂavone values as aglycone equivalents or present
isoﬂavone values with sufﬁcient information so that they can
be readily converted to aglycone equivalents for cross-study
comparison.
Know product constituents that may potentially interact
within soy or with components in food formulations.
Refer to the Consolidated Standards of Reporting Trials
(CONSORT) statement on reporting herbal interventions
(12).
Key points.
Soy intervention products differ chemically.
Published papers often use confusing or incorrect terminology
without precisely specifying what has been used in the study.
Soy provides a variety of potentially biologically active
compounds, including protein, various associated peptides,
and over 100 other phytochemicals, including isoﬂavones.
Interaction can occur among components within a soy product
or with other components in the food or supplement
formulation.
The type and proportion of bioactive constituents will vary
depending on plant genetics, growing and harvesting condi-
tions, storage before and after processing, plant part used,
and processing and extraction methods.
Differences in the physiochemical composition of soy products
may account for differences among clinical and epidemio-
logical studies.
Research articles often use terms such as soy, soy protein, or
even soy supplements without specifying what has been used in a
1194S Supplementstudy. Investigators often neglect to provide sufﬁcient details in
the methods sections of papers to allow others to understand,
interpret, or repeat their work. Consequently, it is possible that
the high degree of chemical heterogeneity among isolated soy
proteins and soy isoﬂavone extracts may have contributed to
inconsistent results noted in meta-analyses and other compila-
tions. Documenting the chemical composition of the test agent
and harmonization of study protocols, including study agents, to
enable cross-study comparison has been called for. Ideally,
journal editors could require these as a condition of publication.
At a minimum, adherence to the CONSORT guidance for
reporting randomized controlled trials of herbal interventions
(12,13) would provide more consistent reporting quality.
Chemical composition. Soy is not a single chemical substance
but is a collection of compounds comprising the soybean. Soy
provides a variety of compounds that have potential biological
activity that cannot be ignored. Components that may have
biological activity include but are not limited to: isoﬂavones,
protease inhibitors, phenolic acids, proteins and peptides, sapo-
nins, phytic acid, phytosterols, lignans, vitamins, minerals, and
other nutrients. This composition is not constant but varies with
thesoybeanstrain,where itisgrown,whenitisharvested, howit
isstoredbeforeandafterprocessing,theplantpartused,andhow
itisprocessedandanalyzed.Factorsaffectingcompositiondueto
processing include method of isolation (e.g. ﬁltration, precipita-
tion), wash steps (e.g. type and quality of solvents), heat, enzyme
treatment, and drying. Compositional changes resulting from
processing include protein and amino acid proﬁle, fatty acid
proﬁle(e.g.oxidation),phytochemicals(e.g.lossesofisoﬂavones,
saponins, phytosterols, oxalates, phytates, etc.), and vitamins
and minerals (e.g. losses and gains) (5,14,15). Consequently, soy
interventionproductsoftendifferchemically.Theseareabsorbed
and modiﬁed differently in the gastrointestinal tract. Knowledge
ofthecompositionofthesoyproductusedinaresearchprojectis
critical, because the proportion of the test product constituents
will vary and may affect study results.
Protein. Several different soy proteins with differing phyto-
chemical proﬁles have been used clinically and in animal studies.
These proteins are primarily identiﬁed according to their
isoﬂavone content. Frequently, isolated soy protein that has
been specially processed to remove essentially all of the
isoﬂavones has been used as a control or negative control to
determine the role of isoﬂavones on health outcomes. However,
such processing removes not only isoﬂavones but other bioac-
tives as well, such as saponins (15,16). Furthermore, the protein
may be denatured and the resulting peptides formed upon
digestion, which are potentially biologically active, altered.
Consequently, conclusions that isoﬂavones are solely responsible
for differences in health outcomes between the effects of
differently processed soy proteins based on their isoﬂavone
content should be made very cautiously.
Isoﬂavones. The soybean contains 12 forms of isoﬂavone
isomers. These include the 3 aglycones (hydrolyzed forms of
isoﬂavones) genistein, daidzein, and glycitein; their respective
b-glycosides genistin, daidzin, and glycitein; and 3 b-glucosides
each esteriﬁed with either malonic or acetic acid (5,17). The type
and concentrations of these isomers in ﬁnished food and
supplement products will vary by the plant part from which
they are derived and the method by which they are processed
(5,18,19). Isoﬂavones inAmerican foodsare primarily present as
glycoside conjugates. The ratio of these conjugates varies in
different soy foods. The levels of the aglycones in supplements
and foods tend to be very low, unless the food is fermented. In
addition, fermentation leads to altered chemistry of the
isoﬂavone (19). Reporting only total isoﬂavones may be inap-
propriate, because the individual isoﬂavones have different
activities.
Furthermore, isoﬂavone content of a product is often
reported without indicating whether the stated amount refers
to aglycone or glycoside. The molecular weight of the aglycone
is ~60% that of the glycoside. Considerably different interpre-
tations may result from an unqualiﬁed statement of isoﬂavone
content. The term “aglycone isoﬂavone equivalents” best
describes the bioactive form of isoﬂavones, because cleavage of
the glycoside to produce aglycone is probably required before
isoﬂavones can be absorbed. As a result, isoﬂavone values
should be reported in such a way that they can be converted to
aglycone equivalents if desired.
Soy exposure and intervention adherence
Guidance.
Identify the food and supplement sources of soy and nonsoy
phytoestrogens available to the study population to deter-
mine the study population’s baseline exposure and to control
and/or monitor nonstudy exposure.
Determine how much nonstudy soy and/or nonsoy phytoes-
trogen exposure will be allowed to establish adherence
criteria.
Key points.
In the United States, mean total isoﬂavone consumption is 1–2
mg/d, whereas in Asian countries, the range is 25–50 mg/d.
Soy and nonsoy phytoestrogens are present in a number of
foods and supplements commonly consumed in the United
States and may inﬂuence study results.
Consumers are not aware of all the soy that they are
consuming, because soy is used as an additive/ingredient
and the soy content varies by food type, brand, year, and
region of the country.
The evaluation of the health effects of soy requires detailed
knowledge of its dietary occurrence and thereby of the exposure
to human populations.
Soy intake/exposure. Data suggest that average consumption
of isoﬂavones in the United States and Europe is 1–2 mg/d
(20,21). Intake varies by age, gender, ethnicity, and socioeco-
nomic status (22). Exposure will also vary by geographic region
of the country. For example, in Hawaii, although Caucasians
have a lower intake of soy compared with Hawaiian Japanese,
Chinese, and Native Hawaiian subpopulations, they have a
higher intake than the mean intake of U.S. Caucasians (23).
When Asians immigrate to Westernized countries, they may
acquire many of the eating habits of the new country’s dominant
culture. This is exempliﬁed by the dietary patterns, including soy
intake, of Japanese women in Hawaii, which are a blend of
patterns seen among traditional Japanese and Hawaiian Amer-
ican Caucasian women (24). Lifestyle factors (e.g. vegetarian-
ism, lignan- and ﬂavonoid-containing supplement use) may also
inﬂuence soy intake (21,25,26).
Most of the epidemiologic research on the relationship
between soy consumption and the development of disease in
humans has been conducted in Asian populations and examined
only the effects of traditional soy foods. Asian populations, in
general, are exposed to soy early in life and consume it over a
lifetime. The total mean intake of isoﬂavones in Asian countries
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(,10%) consuming as much as 100 mg/d (28). Soy intake and
sources vary among Asian countries and among regions within
countries, by age and gender, and over time (27,29–31). Even at
birth, daidzein and genistein are detected in infants’ cord blood,
and these values are similar to the levels in maternal blood (32).
It has been hypothesized that consumption of soy during certain
critical stages early inlife may be responsible forits health effects
later in life.
Food sources of soy and other phytoestrogens. Soy
contains the highest isoﬂavone concentration among foods,
and dietary isoﬂavone exposure occurs mainly through intake of
soy products. Although Asian diets are becoming Westernized,
historically, the type of soy that Asians and Americans eat is
quite different. In Asian countries, soyfoods are generally
minimally processed and often fermented. Japanese, e.g., con-
sume many soy foods in various forms, such as boiled soybeans,
tofu, fried tofu, miso soup, natto, and soy milk (33). Tofu and
miso are the major contributors to their soy isoﬂavone intake.
About 30% of total soy foods consumed by Asians is in the form
of fermented foods (27). Therefore, consumption of isoﬂavone
aglycones is higher in Asian populations, being ~10–30 mg/d
(28).
Americans eat much more processed forms of soy (e.g. soy
ﬂour, textured vegetable protein, and isolated soy protein). The
primary source of isoﬂavones in the United States (56%) is
legumes, presumably soybeans (21). Soy milk is also a signiﬁcant
source (18%). However, recent analysis of the soy and nonsoy
phytoestrogen content (including isoﬂavones) of a wide variety
of foods suggests that phytoestrogen content may be increasing
in a number of foods commonly consumed by the U.S.
population. Soy protein isolate is the sole source of protein in
infant formulas and is a major constituent of many processed
foods. Isoﬂavone intake from these sources may be equal to or
greater than that from foods actually identiﬁed as soy foods. For
example, several meat products and other processed foods,
including sausages, pancakes, baked goods, canned tuna, and
hot dogs, have been reported to contain isoﬂavones because of
their soy additives (16,34). These hidden sources of soy will vary
by brand and the same branded product will change composi-
tion over time and by region of the country (35). In addition, the
number of new products introduced into the market annually is
substantial (36).
The importance of the hidden sources is tempered by the fact
that many of these foods contain isoﬂavone levels below our
limit of reliable detection. Nonetheless, given the comparatively
high levels of isoﬂavone excretion observed among some
nonAsian women who generally do not consume traditional
soy-based products, there is a need to examine a wide variety of
foods when evaluating the relationship between isoﬂavone
exposure and a health outcome (26,37,38). Foods other than
the traditional soy-based ones may be major contributors to
isoﬂavone exposure in most Western populations. Accurately
quantifying isoﬂavone intake when exposure to easily identiﬁ-
able soy products is low is extremely difﬁcult.
Nonsoy foods may contribute to phytoestrogen intake and
may inﬂuence study results. In many Western diets in which
soybeans do not contribute substantially to the diet, lignans are
the phytoestrogens that are primarily consumed and provide the
major source of phytoestrogens (34,39). Some foods that
contain low concentrations of lignans, such as fruits, vegetables,
and beverages, are consumed in large amounts and can
contribute signiﬁcantly to lignan intake. Major sources are
coffee and orange juice, not because these foods are high in
lignans, but because they are frequently consumed (37). Nonsoy
isoﬂavone intake from other foods, including cereals and breads,
eggs, dairy products, meat, ﬁsh, nuts, and vegetables, has been
documented (40–45).
Dietary supplement sources of soy and other phytoes-
trogens. In addition to foods, soy dietary supplements, espe-
cially in certain populations, may contribute signiﬁcantly to
isoﬂavone intake and other nonsoy phytoestrogen intake, in
general. The soy supplement market is not as large as the overall
soy food industry and has been declining (46) but is nonetheless
substantial with .50 different preparations available. Some
supplement products also have soy-like isoﬂavones. Kudzu
contains very high levels of daidzein and puerarin, which is a
methoxylated derivative of daidzein. Red clover is also found in
supplements and includes formononetin and biochanin A, which
are methoxylated forms of genistein and daidzein. In the absence
of a comprehensive assessment, studies (particularly in non-
Asian populations) could suffer from the effects of uncontrolled
confounding by unrecognized and unmeasured sources of
phytoestrogen exposure potentially leading to biased estimates
of effect and misinterpretation of ﬁndings.
Assessing exposure and adherence
Guidance.
Validate dietary assessment methods speciﬁc to soy and/or
nonsoy phytoestrogen intake in relationship to timing,
frequency, study population characteristics, and geographic
region.
Assess isoﬂavone metabolites in biologic ﬂuids (optimally both
blood and urine), and target tissues, as appropriate, to
improve study and nonstudy exposure assessment.
Key points.
Dietary assessment methods can be used to determine prior or
lifetime exposure to soy and nonsoy phytoestrogens, distin-
guish high from low consumption, capture dietary supple-
ment use, and monitor adherence.
Dietary assessment requires food composition databases that
are a challenge to keep up-to-date and which contain
isoﬂavone values for only a select number of foods.
Food composition databases can be useful in identifying soy
food and soy and nonsoy phytoestrogen (including isoﬂa-
vone) sources.
Urine can be a good predictor of systemic availability of soy
isoﬂavones.
Control and/or monitor nonstudy exposure to soy and
nonsoy phytoestrogens using study-appropriate assessment
methods.
Dietary assessment. Dietary assessment methods can be used
in intervention studies to determine prior or lifetime exposure to
soy, distinguish high from low consumption, and monitor
adherence. Dietary assessment methods include FFQ, 24-h
recalls, and dietary records. Each method has strengths and
limitations and may be used differently depending on whether
the assessment determines long- or short-term intake, is for
individuals or groups, distinguishes very high from very low soy
consumption, is for very accurate or general consumption,
identiﬁes soy supplement or soy food intake, etc. In addition, the
foods commonly available and consumed in the study geo-
graphic region may be an important variable in determining
which method is appropriate. Choosing a method with repro-
1196S Supplementducible data, especially in a population similar to the study
population, is important.
Validation of assessment instruments is difﬁcult because,
despite the availability of urinary and plasma biomarkers, the
short half-life of isoﬂavones and their metabolites limits the use
of these biomarkers for validation if consumption of soy is only
occasional. In addition, urinary isoﬂavones may be less fre-
quently correlated with a soy questionnaire among low con-
sumers, because isoﬂavones from soy additives, such as those in
breads, meats, or canned foods, are detected in urine but are not
captured in FFQ or recalls. Thus, carefully designed assessment
methods may be required to obtain such information.
For dietary assessment, a sufﬁcient number of data collection
points is needed. This will be inﬂuenced by the dietary assessment
method used. Which instrument is used will depend on the study
population and the inclusion of the relevant foods and supple-
ments. One must keep in mind that a gram of a soybean or soy
food is not a unit of amount of isoﬂavones; that is, the amount of
isoﬂavones doesnotparalleltheamount of soyfood.This calls for
the augmentationof assessment instruments by analysis ofwhat is
being eaten by the study participants. Both the frequency of
consumption and the soy content have measurement issues.
Assessment in biologic ﬂuids. Isoﬂavones in urine and
plasma have been used in a number of studies as a biomarker
of soy food or isoﬂavone intake (32,47). There is a good
correlation between peak concentrations of plasma daidzein and
genistein and their concentrations in the ﬁrst 24-h urine
following soy consumption (48). In populations that consume
small to moderate amounts of soy only occasionally, different
methods of adherence assessment may be necessary, because
urinary isoﬂavones reﬂect primarily the intake within the past
48 h. Multiple urine collections could correct this drawback but
may not be feasible.
The use of spot urine samples for isoﬂavone measurements
may be problematic. There is a poor correlation between spot
urine isoﬂavone levels and peak plasma concentrations of
isoﬂavones. An example of this problem with spot urine
collection is illustrated by a study of women in Gifu, Japan
(24). Although urinary isoﬂavone assessment conﬁrmed the
validity of soy consumption measured by the FFQ, the difference
in mean urinary isoﬂavone excretion between groups was
considerably greater than the difference in self-reported soy
intake. This was most likely a result of the women donating
urine samples each morning, typically after a breakfast of tofu
and/or miso soup, when isoﬂavone excretion peaked.
The advantages and disadvantages of using plasma, urine,
and/or target tissue for assessment of isoﬂavone bioavailability
need to be considered and include the invasiveness of the
method, ability to identify equol producers, ability to collect a
more concentrated matrix (e.g. overnight urine), participant
control over collection, privacy of collection, and how well the
method reﬂects exposure over the course of the study. For more
information on isoﬂavone bioavailability, see the “Pharmacoki-
netics” section in this document.
Food composition databases. Analysis of the dietary intake
will rely on a food composition database that should contain a
representative sample of soy foods. Conﬂicting results from
epidemiologic or clinical studies may in part be related to food
sources or databases used in estimating phytoestrogen intake.
Studies illustrate large variability in the isoﬂavone content of
isolated soy proteins and reinforce the need to accurately de-
termine the isoﬂavone content of foods and dietary supplements
used in dietary intervention studies while exposing the limita-
tions of food composition databases for estimating daily
isoﬂavone intakes (35).
Food composition databases can be useful in identifying
some soy and nonsoy phytoestrogen sources. Consideration
should be given to analyses of major sources. To do this, these
sources should be speciﬁcally deﬁned and the analytical methods
well described. Databases can be used for quantifying the minor
phytoestrogen sources without conducting further analyses.
Despite the usefulness of databases, the variability in isoﬂavone
values in foods limits the usefulness of a database for interven-
tion studies or even for intake assessment studies. One must keep
in mind that each country’s food composition tables is based on
different chemical analyses, conversion factors, products, and
deﬁnitions (49,50). The food composition databases developed
and maintained by the USDA report values for genistein,
daidzein, glycitein, coumestrol, formononetin, and biochanin
for selected foods and with well-documented methodology (51).
Foods that may contain small amounts of these constituents, but
that may be consumed frequently, are not included.
Analytical methods
Guidance.
Identify constituents in the study product that should be and
can be analyzed.
Consider constituent characteristics, both biochemical and
physical, when choosing appropriate analytical methods.
Choose analytical methods that are precise, accurate, reliable,
valid, and validated for the analyte and matrix.
Establish speciﬁcations for laboratory performance of chosen
analytical methods.
Include the use of internal and external standards and
reference materials for instrument calibration and method
accuracy.
Key points.
Investigators in the past provided insufﬁcient details on
product composition in papers to allow others to under-
stand, interpret, or repeat their work.
Analyzing or reporting only total isoﬂavone content of the
study agent does not provide a complete characterization of
the product.
When evaluating past studies, if the study product is still
available, consider analyzing the study product for critical
constituents.
Sample preparation and conservation is particularly impor-
tant, because some isoﬂavones are relatively unstable and
adequate storage conditions are necessary.
There is considerable variability across laboratories using
reliable, valid analytical methods.
A good understanding of the absorption, distribution,
metabolism, elimination, and bioavailability of soy is needed
and demands reliable, precise, accurate, valid, and validated
analytical techniques applicable to a wide variety of food,
supplement, and biological matrices.
Foods and dietary supplements. Soy isoﬂavone and protein
products should be characterized by clearly deﬁned attributes
that allow comparison among studies. The provision of accurate
data on the phytoestrogen/isoﬂavone content of different foods,
soy protein isolates, and supplements has been hampered until
recently by the availability of suitable validated analytical
methods. Several reviews have assessed currently available
methods (15,52–55).
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beans, soy foods, and dietary supplements, as well as in other
samples, will enable researchers to correctly evaluate the
inﬂuence of these phytochemicals on health as well as provide
precise dietary and safety guidelines on the consumption of these
compounds. Most importantly, the scientiﬁc community, in-
cluding academics, industry, journal editors, and reviewers,
must recognize that the validation, preservation, and extraction
of samples are critical steps in describing the content of
isoﬂavones and/or protein used in research (15,49).
Challenges to getting good numbers exist and laboratories
may poorly perform otherwise reliable, valid analytical
methods. First and foremost, sample conservation is particularly
important and adequate storage conditions are necessary to
preserve the original compositional proﬁle of soybeans and soy
products. Inadequate conservation and storage are major
contributors to the misreporting of product composition despite
the adequate performance of appropriate analytical methods.
Additional challenges include extraction methods, sample prep-
aration, and use of internal standards (49,55). Isoﬂavone
degradation can occur during the processing of the sample,
because soy some isoﬂavones are relatively unstable. The
isoﬂavones most susceptible to degradation may be the malonyl
forms. Glucoside and aglycone concentrations may increase
(49). Internal standards are critical to correct for the dilution
volume and also to determine the repeatability of the method.
Without internal standards, high accuracy of isoﬂavone analysis
is not achievable. Each step of an analytical method must be
carefully observed and documented. Otherwise, the results may
not be reproducible by others and will introduce misinformation
in the scientiﬁc literature (49). Clinical investigators should
include analysts and/or natural products chemists on their study
team to determine appropriate storage conditions, including
temperature and humidity. Prior to conducting the study, they
should consider performing stability studies on the study agents,
monitoring stability throughout the study, and developing
speciﬁcations for the amount of degradation allowed.
Biologic ﬂuids. Conﬂicting results arising from the use of only
1 method of assessment underscore the importance of having
multiple adherence or exposure measures, each with a different
source of error. Optimally, collection of both blood and urine
collection may be considered for future clinical studies.
Isoﬂavones and their metabolites occur in relatively high
concentrations in plasma, urine, and to a smaller extent in
feces, and can be measured.
Many epidemiological studies rely almost entirely on spot
urines. Even when 24-h urine collections are obtained, an
exogenous marker, e.g. para-aminobenzoic acid, is lacking.
Internal standards are critical to standardizing methods, because
there are many variables that must be considered. An isotopically
labeled internal standard for each analyte allows traceability. An
external standard is necessary to ensure that the method consis-
tently provides the same answer, i.e. the method when performed
correctly is precise. Calibration materials will provide assurance
of accuracy. An extensive review of techniques applied to
phytoestrogen(includingisoﬂavone)analysisthatfocusesprimar-
ily on the analysis of biologic ﬂuids has been published (56).
Reference materials. Reference materials are substances with
1 or more values that are sufﬁciently homogeneous and well
established to be used for the calibration of equipment, the
assessmentofameasurementmethod,ortheassignmentofvalues
tomaterials.Areference materialaccompaniedbyacertiﬁcateof
analysis, which establishes analytical values with a stated level of
conﬁdence, is referred to as a certiﬁed reference material. Both
typesareavailablecommercially.Astandardreferencematerialis
a very speciﬁc type of certiﬁed reference material and is only
producedbytheNationalInstitutesofStandardsandTechnology.
These standard reference materials may be used as calibration
solutions and internal standards, for method development/
quality control, and to provide traceability. National Institutes
of Standards and Technology is currently developing natural
matrix standard reference materials for soy products. The soy
suite will include soy ﬂour, soy milk, soy protein isolate, soy
protein concentrate, and soy-containing solid oral dosage form,
and will be certiﬁed for isoﬂavones, fatty acids, vitamins,
elements (minerals), amino acids, and proximates.
Pharmacokinetics
Guidance.
Determine bioavailability as part of each intervention study to
assist in interpretation of variability in results.
Determine dose, dose schedule, and intervention duration
based on quality preliminary human data.
Stratify for equol-producer status with sufﬁcient statistical
power to reduce variability in clinical outcomes.
When collecting biologic ﬂuids, allow enough time to lapse
after initial soy intake to ensure that measurements will
reﬂect the intake.
Key points.
Understanding bioavailability may help optimize the health
effects and interpret variability in study results.
Fractional absorption of isoﬂavones decreases with increasing
dose.
Several doses throughout the day may help maintain optimum
steady-state isoﬂavone levels.
Isoﬂavones from different foods and supplements have differ-
ent rates of absorption.
The behavior of isoﬂavone aglycones and glycosides differs, as
does their metabolism.
About 30% of individuals have the capacity to produce equol
and such individuals will contribute variability in study
results.
Most soy ingredients act by different modes of action, may act
by more than 1 mechanism, and may signiﬁcantly interact.
Many papers, often with conﬂicting results, have been
published about the relationship between soy and health-related
endpoints. Investigators often apply a reductionist approach to
studying soy, which might contribute to conﬂicting results. They
assume that: 1) the effects of feeding a soy food reﬂect the
activity of 1 or a small number of related soy components; 2) the
activity of a puriﬁed soy component reﬂects the effects of eating
whole soy foods; and 3) soy foods or supplements equal
isoﬂavones that are estrogenic or antiestrogenic, which explains
the biological effects of soy consumption. Animal studies
demonstrate these assumptions are false (57–61). Bioavailability
and potential modes of action of various soy constituents differ.
Most ingredients act via more than 1 mechanism (62). In
addition, soy constituents may potentially interact synergisti-
cally in maintaining/obtaining study endpoints.
It is very important to understand factors that inﬂuence
bioavailability and modes of action. A homogeneous study
group based on phenotypic expression of a health characteristic
will be quite heterogeneous genotypically. This may explain why
the outcomes of studies are sometimes conﬂicting. Moreover,
differences in individual lifestyles, nutrition habits, and speciﬁc
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groups, which leads to debatable efﬁcacies of the constituents
tested. Other factors affecting bioavailabilityand mode of action
include the chemical composition and matrix of the soy product,
dose, interaction with other components in product formula-
tion, oral antibiotic use, participant exposure history, and
additional participant characteristics, such as age, gender, and
ability to produce equol, a biologically active metabolite. An
understanding of these factors is required to predict the risk of
adverse effects and to optimize the potential health effects of
these compounds by ensuring that sufﬁcient concentrations are
reaching the target tissue. It may also help in the interpretation
of the variability and results that we see among clinical trials.
Soy protein isolate. Soy protein or peptide components may,
in addition to isoﬂavones, be responsible for soy’s purported
health effects (57,63,64). There are several mechanisms by which
protein/peptide components (b conglycinin, small water-soluble
peptides, amino acid proﬁles, phytochemical components other
than isoﬂavones) may be biologically active. The protein
b conglycinin (7S globulin) constitutes 40–60% of the total
protein in soy. Hydrolysates and b conglycinin-derived peptides
have been reported to have biological effects in vitro. However,
very few studies of this protein have been conducted in animals
(65–67) or humans (68) and their results have shown equivocal
effects. The problem is that it is unclear whether or not these
peptides are actually formed by digestion by the gut in vivo and
whether or not they are bioavailable and at what concentrations.
There are a number of small water-soluble peptides (e.g.
Bowman-Burke inhibitor, Kunitz inhibitor, Lunasin) that are
associated with soy protein isolate (69,71). However, their
bioavailability is questioned and their bioactivity cannot be
realized without extremely large doses of soy protein isolate.
The same pattern of amino acids in plasma is likely to be
different from the pattern shown after ex vivo hydrolysis of the
proteins because of differences in amino acid absorption and
hepatic metabolism and transport in vivo (71).
Phytochemical components of soy protein isolate other than
isoﬂavones may have biological activity. Intact soy protein
isolate induces cytochromes P450 CYP3A1 and CYP1A1 and
carnitine palmitoyltransferase, whereas the stripped soy protein
isolate, which is processed to have negligible levels of phyto-
chemicals, including isoﬂavones, has a lesser or no ability to
induce these proteins. Levels of genistein or daidzein in amounts
equivalent to that in intact soy protein isolate also do not induce
these proteins, indicating that something other than the
isoﬂavone in the soy protein isolate is responsible (60,72,73).
Isoﬂavones. Isoﬂavones from different foods and supplements
have different rates of absorption. The differences are attribut-
able to differences in gastric emptying related to the food or
supplement matrix and differences in intraluminal dissolution of
the isoﬂavone from the matrix (74–76). In addition, fermented
foods, with greater aglycone content, may be absorbed more
rapidly than foods composed primarily of glycosides (75,76);
however, more recent data shows this not to be the case (48). In
addition, current data are equivocal as to whether the bioavail-
ability of isoﬂavones from soy foods differs from that of
supplements (76–79).
Controversy exists regarding the extent of bioavailability of
isoﬂavone glycosides and the mechanism of intestinal absorption
of isoﬂavones in humans is unclear. Isoﬂavone glycosides are
basically biologically inactive and are not absorbed intact across
the enterocyte of healthy adults, and their bioavailability
requires initial hydrolysis of the sugar moiety by intestinal
b-glucosidases for uptake in the peripheral circulation (80). The
aglycones are bioavailable and biologically active.
A biphasic isoﬂavone appearance in urine and plasma when
humans consume soy or puriﬁed isoﬂavones has been observed
(81). Patterns in plasma and urine are correlated. There is an
initial rapid surge uptake of isoﬂavones, at 1–2 h and a second
peak at 4–8 h. The initial peak representing ~10% of the overall
uptake probably reﬂects absorption of aglycones without
hydrolysis in the proximal intestine, although recent data
challenges this explanation (81). Uptake in the proximal small
intestine may indicate a saturation limit, because even bioavail-
able aglycones are absorbed only partially in the small intestine.
The initial hydrolysis of the sugar moiety may not be the rate-
limiting step in initiating plasma levels. The majority of
isoﬂavones is absorbed after hydrolysis in more signiﬁcant
amounts in the more distal intestine, predominantly the large
intestine. Fractional absorption decreases with increasing dose.
There may be no advantage to larger doses. In addition, studies
of high and low doses indicate that steady-state serum levels
could be maintained if doses are divided or taken several times
throughout the day rather than via a single bolus dose (74).
Isoﬂavone half-life in humans is 7–9 h. In general, plasma
genistein levels are consistently higher than plasma daidzein
levels for equimolar doses, because the volume of distribution of
genistein is less than the volume of distribution of daidzein. The
clearance rate of daidzein is much faster than the clearance rate
of genistein. The clearance rate for equol is even slower, and
equol levels for the same concentration attain much higher
values. Equol is far more bioavailable.
Equol. Equol production may provide a clue to the inconsis-
tency among some clinical study results and disparity between
observation and clinical ﬁndings. Daidzin and daidzein are the
precursors of equol, which is exclusively a product of intestinal
bacterial metabolism. It is not produced in germ-free animals,
newborn infants whose gut is not yet colonized by microﬂora,
and many adults. Following ingestion of a deﬁned dose of
daidzein or soy foods, there is a wide interindividual variability
in the ability to produce equol. There is little difference between
males and females, although there is a tendency for males to
have a higher propensity to make equol than females (82).
Infants with immature gut ﬂora (83) and older adults whose gut
ﬂora may be compromised or with alterations in intestinal
morphology (84) may have altered absorption or conversion to
equol. There may be greater absorption in children compared
with adults due to more efﬁcient hydrolysis or slower degrada-
tion (85). However, the greater absorption could be due to the
“grazing” nature of children’s eating behaviors. There appear to
be no differences in pharmacokinetics between pre- and post-
menopausal women (74,75).
In the United States and other Western populations, the
overall frequency of equol producers is ~30%. Around 50–60%
of Asians make equol and ~60% of vegetarians make equol
when consuming soy (86). The reason for these differences is not
understood. One reason may be that dietary factors inﬂuence
equol production. Clinical studies may beneﬁt from a pretest for
equol producers, which would consist of repeated administra-
tion of a soy challenge for several days before actually collecting
samples to determine whether equol is present or not. Further-
more, studies could stratify by equol-producer status, which
may reduce variability in clinical studies.
There is a time-dependent conversion from daidzein to equol.
Equol production occurs somewhat distally in the intestine,
NIH workshop guidance on clinical studies of soy 1199STABLE 1 Summary guidance from an NIH workshop on designing, implementing, and reporting clinical
studies of soy interventions
Summary
I. Introduction/background
Use caution when interpreting past studies; consider study age, source, and quality, historical changes in test agents, background influences, participant characteristics
and heterogeneity, and intervention adherence and frequency of its assessment.
Acquire information from previous studies on product characterization, stability, and analytical methods used to determine product integrity.
Use preclinical and epidemiological data only if they are predictive of human response in the proposed study population.
Use data from studies that investigated products relevant to the proposed health outcome of interest and to the proposed soy intervention.
Determine if pharmacokinetic and bioavailability studies support the proposed study hypothesis.
Document that Phase 1 studies have been completed or whether the safety of the test agent has been established.
II. Methods
A. Participants
Consider the appropriate homogeneity or heterogeneity of the proposed study population.
During screening, identify subgroups, e.g., equol producers, that may have greater or lesser response to soy.
Take advantage of special homogeneous populations with higher and/or constant exposure to understand the gene-soy interaction.
Consider establishing eligibility criteria based on recruits' previous exposure to soy (when and for how long this occurred, how much, and type of soy).
Consider the requirement that study recruits be subjected to a washout period or discontinue foods or supplements containing soy prior to randomization.
Develop eligibility criteria relevant to intake of foods or supplements containing soy, its constituents, or other ingredients (e.g. other phytoestrogens) with similar
mechanisms of action for the duration of the study.
Consider how to address oral antibiotic use, other prescription drugs, or over-the-counter preparations that may confound study results.
B. Intervention
Refer to the CONSORT statement on reporting herbal interventions (13).
Do not test purified constituents to answer questions related to food or complex product intake.
Determine study purpose, hypothesized or actual mechanism(s) of action of soy constituents on study endpoints before selecting the test agent.
Understand how soy processing impacts the study outcome and choice of test agent
Consider both biochemical and physical properties in choosing a test agent.
1. Product name
Use appropriate and accurate terminology in describing test agents.
2. Product characteristics
Know and report the product source and supplier.
Analyze, describe, and report all the potential bioactive constituents relevant to the study.
Express isoflavone values as aglycone equivalents or present isoflavone values with sufficient information so that they can be converted to aglycone equivalents
for cross-study comparison.
3. Dosage regimen and quantitative description
Determine dose, dose schedule, and duration of administration based on quality preliminary human data, including dosing or dose ranging studies, sufficient to
achieve a steady state and appropriate for the study hypothesis.
Consider the clearance rate of active constituents or their metabolites in selecting the dose.
Determine if the matrix in which the test agent is administered (e.g. in or with food, as a supplement) influences the frequency and timing of administration.
Determine habitual diet and/or gut microflora in selecting dose and mode of administration.
Evaluate the acceptability of the dose and administration schedule.
4. Qualitative/quantitative testing
Identify constituents in the study product that should be and can be analyzed.
Consider proximate composition (protein, carbohydrate, fiber, and fat).
Choose analytical methods that are precise, accurate, reliable, valid, and validated for the analyte and matrix.
Establish specifications for laboratory performance of chosen analytical methods.
Include the use of internal and external standards and reference materials for instrument calibration and method accuracy.
Conduct independent analyses of test and placebo agents before, during, and after intervention, and report all analytical methods used to determine product constituents.
Store samples of the test product appropriately for future analysis if new analytical methods are developed, new constituents discovered, or questions arise that
require additional analyses.
5. Intervention adherence
Consider the impact of nonstudy soy and/or nonsoy phytoestrogen exposure on the study outcome.
Identify the food and supplement sources of soy and nonsoy phytoestrogens available to the study population to determine the study population's baseline exposure and to
control and/or monitor nonstudy exposure.
Determine how much nonstudy soy and/or nonsoy phytoestrogen exposure will be allowed to establish adherence criteria, taking into consideration measurement error
and variability.
Validate dietary assessment methods specific to soy and/or nonsoy phytoestrogen intake in relationship to timing, frequency, study population characteristics,
and geographic region.
Assess isoflavone metabolites in biologic fluids (optimally both blood and urine) and target tissues, as appropriate, to improve study and nonstudy exposure assessment.
When collecting biologic fluids, allow enough time to lapse after initial soy intake to ensure that measurements will reflect the intake.
Understand how dietary assessment and analytical methods compare with those used in previous clinical studies.
(Continued)
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d 2 and 3 following ingestion. This is important for intervention
and epidemiological studies. Sampling of biologic ﬂuids needs to
occur far enough after initial intake to ensure that measurements
will reﬂect the intake (74–76).
Genetic polymorphisms
Guidance.
Increase sample size to understand gene-soy interaction.
Simultaneously investigate gene-gene, gene-diet, and diet-diet
interactions.
Key points.
Homogeneous study groups based on phenotypic expres-
sion of a health characteristic will be quite heterogeneous
genotypically.
Genetic makeup may play a major role in the inconsistent
ﬁndings from human studies, including clinical and epidemio-
logic studies. Studying thegenetic polymorphisms mayhelp us to
understand why the variations in results exist. The human body
has .25,000 genes and each gene has many polymorphisms.
Genotypes, which consist of single nucleotide polymorphisms,
are functional and inﬂuence nutrient-gene interactions that
determine the internal dose of exposure for the response. For
example, people with different genetic proﬁles may have higher
or lower metabolic capabilities, which leads to the differential
dietary requirement for the same effects. It is generally accepted
that genotypes are not directly related to social status or lifestyle
factors. However, some of the single nucleotide polymorphisms
are known to be associated with the utilization and/or metab-
olism of dietary components, as well as the development of
various diseases. Randomization to different soy exposure levels
by genotypes may provide us with insights into the susceptible
population to soy-related disease risk.
The following provides an example. Isoﬂavones have both
antiestrogenic and estrogen-like effects depending on the en-
dogenous estrogen level. Endometrial cancer is a sex hormone-
related disease. Isoﬂavones may reduce endometrial cancer risk
by interfering with the synthesis, metabolism, and signal trans-
duction of steroid hormones. Soy interacts with several estrogen-
related genes, such as UGT1, HSD17b1, and CYP19A1 in
endometrial cancer. In vitro studies have consistently found
that isoﬂavones inhibit 17b-hydroxysteroid dehydrogenase type
I activity, the key enzyme in the last step of estrogen synthesis,
catalyzing estrone to the biologically more active estradiol in
estrogen-susceptible tissues. Recently, a large-scale, population-
based, case-control study demonstrated that isoﬂavones interact
with the sex hormone-binding globulin polymorphisms in the
development of endometrial cancer (87,88). The investigators
found that the ASP
327ASN polymorphism modiﬁed associations
of soy isoﬂavones with endometrial cancer, with the inverse
association of soy intake, especially in women with low
endogenous estrogen and low soy intake (87). Isoﬂavones may
act through multiple mechanisms to reduce carcinogenesis and it
is possible that the effect of this polymorphism is obscured bythe
competing pathways under conditions of high estrogen or
isoﬂavone exposure (88).
Guidance summarized
Study design characteristics may account for conﬂicting results
among soy clinical studies. A major challenge is the need to have
sufﬁcient statistical power to make ﬁrm conclusions. In studies
with relatively small sample sizes, variation could easily
contribute to inconsistent clinical results. Contributors to
variability have been addressed in previous sections and include
product composition, whole soy compared with isolated con-
stituents, dose, duration of intervention, previous exposure to
soy, nonstudy exposure to soy and other nonsoy phytoestrogens,
equol producers compared with nonproducers, interactions with
drugs (e.g. antibiotics) or food and supplement components,
isoﬂavone metabolism, genetics, and measurement error. Work-
shop participants made many suggestions and recommendations
for the design, implementation, and reporting of soy clinical
studies, all of which cannot be addressed in depth in this report.
Table 1 consolidates the previously identiﬁed suggestions and
the remaining suggestions identiﬁed at the workshop. These are
formatted similarly to the CONSORT recommendations on
TABLE 1 Continued
Save biologic tissues for future analysis when methods for metabolites are developed or new metabolites discovered.
When choosing methods to assess adherence, balance acceptability, feasibility, frequency or number of measurements, and appropriateness and validity of the method.
C. Outcomes
Assess safety, in particular address the effects of high levels of soy intake following long-term soy exposure.
Simultaneously investigate gene-gene, gene-diet, and diet-diet interactions.
Determine bioavailability as part of each intervention study to assist in interpretation of variability in results.
Determine the influence of gut microflora on bioavailability and metabolism of soy or its constituents, and the influence of soy on gut microflora.
D. Sample size
Increase sample size to understand gene-soy interaction.
Consider variability of response when determining sample size and expected effect size.
E. Statistical methods
Analyze health outcomes in relationship to serum isoflavone level because serum levels of daidzein and genistein are directly related to efficacy.
Stratify for equol-producer status with sufficient statistical power to reduce variability in clinical outcomes
Power the study to analyze predefined subgroups separately.
III. Reporting results
Refer to CONSORT statement on reporting clinical studies, which serves as a useful tool in designing the trial as well as reporting results (12).
Address potential confounding factors such as the isoflavone profile of the intervention product, isoflavone dose, and participant characteristics (e.g. genotype).
IV. Investigators
Compose the multidisciplinary investigative team to include sufficient expertise to address study design and statistical issues, interpretation of past studies upon which
the current study is based, product composition and integrity, assessment of exposure or protocol adherence, as well as the disease or health conditions being studied.
NIH workshop guidance on clinical studies of soy 1201Sreporting clinical studies (12). Workshop participants empha-
sized that investigators should follow Good Clinical Practices
(89) in designing and implementing soy studies and the
CONSORT recommendations (12,13) when reporting clinical
investigations of soy. This guidance is intended to improve the
quality of clinical studies of soy interventions and may be used as
a tool by study investigators, protocol reviewers, sponsors, and
journal editors.
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